SCHEMBL5043437

SCHEMBL5043437

COc1ccc(C#Cc2ccc3c(c2)OCC(C)(C)CO3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.51
APP P05067 2/20 0.44
HTR2B P41595 2/20 0.39
SIGMAR1 Q99720 2/20 0.39
HTR1A P08908 1/20 0.39
ATM Q13315 1/20 0.39
RARA P10276 1/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39
KCNH2 Q12809 1/20 0.39
GRM3 Q14832 1/20 0.39
HTR7 P34969 1/20 0.39
TMEM97 Q5BJF2 1/20 0.39
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
PKM P14618 3/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5043653 0.87 CA12 (0.46) ACACBHTR2BSIGMAR1HTR1AHTR7
SCHEMBL5043403 0.86 ACACB (0.52) ACACBNPC1RAB9AMEN1KMT2A
SCHEMBL5048237 0.85 ACACB (0.49) ACACBAPPRAB9AMEN1KMT2A
SCHEMBL3671715 0.84 ATM (0.50) APPATMNPC1RAB9APKM
SCHEMBL5043671 0.83 ACACB (0.50) ACACBNPC1RAB9AMEN1KMT2A
SCHEMBL5046911 0.83 ACACB (0.53) ACACBATMALDH1A1HPGD
SCHEMBL5043428 0.82 ACACB (0.49) ACACBNPC1RAB9AKDM4EALDH1A1
SCHEMBL5046845 0.82 ACACB (0.56) ACACBAPPHTR2BSIGMAR1RARA
SCHEMBL5046828 0.81 ACACB (0.48) ACACBSIGMAR1KCNH2
SCHEMBL5043418 0.80 ACACB (0.47) ACACBPKMMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US claimed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP claimed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US claimed
US-7459480-B2 Benzodioxepine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-12-02 US disclosed
EP-1682528-B1 BENZO [b][1,4] DIOXEPINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-09-12 EP disclosed
US-20050113374-A1 Benzodioxepine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113374-A1 Benzodioxepine derivatives BBOX1, ACOX1, ACOX3 ACACB 5/4885APP 207/4885HTR2B 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.